Vancouver, BC – October 25, 2017: Liberty Leaf Holdings Ltd. (CSE: LIB, OTCQB: LIBFF and FSE: HN3P) (the “Company” or “Liberty Leaf”) & Mr. Robert Laurie, Advisory Board Chair, are pleased to announce the addition of Dr. Mary Fitzpatrick to the Company’s newly formed Advisory Board.
Liberty Leaf is taking an active role in advancing research into veterinary cannabis use with its three-year collaborative agreement with ESEV, a leading Israeli-American research and development company. Liberty Leaf has appointed Ms. Fitzpatrick to the Advisory Board in order for her to provide expertise in animal health in regards to the efficiency of CBD pain management for canine osteoarthritis. This research presents Liberty Leaf an opportunity to generate sales within the $105B global pet health and wellness industry.
With a career spanning 38 years, Dr. Fitzpatrick has experience providing veterinary services to a diverse mixture of animals ranging from pocket pets to zoo animals. Her primary focus of interest is on companion animals and providing a pain-free existence during their senior years. Having Dr. Fitzpatrick’s insight and participation will advance Liberty Leaf and its partner, Esev, to develop dosage guidelines for household pets.
Dr. Fitzpatrick formerly owned Spanaway Veterinary Clinic in Spanaway, Washington, U.S.A. There, she developed the enterprise from a “one doctor strip mall” practice to a free-standing veterinary hospital with 26 employees. With the success of the hospital, Dr. Fitzpatrick was able to sell the practice in 2015 for seven times the original purchase price in 1987. This success has now allowed her to focus more time into her passion of exploring ways to improve the life of companion animals.
“Current pain relieving methods in companion animal medicine rely heavily on drugs that can have a host of negative side effects. Opioid medications often cause such sedation and nausea that the quality of life for the companion animal is negatively affected. The positive effects of cannabis containing preparations for pain relief need to be scientifically explored, allowing for more choices in pain relief for our four legged friends,” states Dr. Fitzpatrick.
Liberty Leaf’s new member of the Advisory Board holds a Doctor of Veterinary Medicine (Cum Laude) and a Bachelor of Science from the Washington State University, graduating in 1979.
“We at Liberty Leaf are extremely gratified to welcome Mary to the team,” said President and CEO, Will Rascan. “Her input will add immense experience and knowledge to our Esev venture as we continue.”
Liberty Leaf anticipates the announcement of four to six members to the Advisory Board over the coming months. The members selected will possess abilities and skills related to the cannabis business that are unique in nature and will add value to the Company.
The Liberty Leaf Advisory Board will vet potential business opportunities, discover and conduct due diligence on potential value-added synergistic targets, and foster new relationships that will further the Company’s presence within the global cannabis industry.
About Liberty Leaf
Liberty Leaf Holdings Ltd. is a new Canadian-based, public company whose focus is to build and support a diversified portfolio of cannabis-sector businesses, including cultivation, value-added CBD/THC products, biotech research and supply chain products within this dynamic and fast-growing sector.
Liberty Leaf also owns 100% of North Road Ventures, a late-stage applicant under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR).
On behalf of the Board
President & CEO
Liberty Leaf Holdings Ltd.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements.